Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
Br J Haematol
; 191(3): 386-389, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: covidwho-697165
ABSTRACT
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Linfoma de Células B Grandes Difuso
/
Pandemias
/
Linfoma Plasmablástico
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Estudios diagnósticos
/
Estudio observacional
/
Estudio pronóstico
Tópicos:
Covid persistente
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Br J Haematol
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Bjh.17066
Similares
MEDLINE
...
LILACS
LIS